Anemia is a condition where blood is deficient in red blood cells (RBCs). Pernicious anemia occurs when the body’s capacity to absorb vitamin B12, which is required to make healthy red blood cells, is reduced. It is a rare condition. As per the Journal of Blood Medicine, the prevalence of pernicious anemia is about 0.1% in the normal population, while in aged people (people over 60 years) the prevalence is about 1.9%. Previously, the disease was incurable due to lack of available treatment options. However, it is now easily treatable due to availability of medicines.
The symptoms of pernicious anemia are not severe initially, and therefore it is difficult to diagnose. Commonly occurring symptoms include weakness, headaches, weight loss, and in rare cases some neurological problems. The most important sources of vitamin B12 include meat, eggs, poultry, dairy products, and nutritional supplements. In moderate to severe cases, vitamin B12 injections are provided to the patient to counteract deficiency symptoms. Vitamin B12 is available in the form of cyanocobalamin or hydroxocobalamin injections. When vitamin B12 levels are close to normal after treatment with injections, oral doses in the form of pills, sprays, and gels can be provided.
High prevalence of the condition is a major factor likely to drive the global Pernicious Anemia Treatment Market during the forecast period. Development of pipeline products, high number of women of reproductive age, unhealthy lifestyle, and complications during pregnancy primarily in developing countries are some of the factors expected to propel the global pernicious anemia treatment market during the forecast period. Furthermore, increase in geriatric population, robust R&D, and improving health care infrastructure are projected to boost the global pernicious anemia treatment market. However, factors such as lack of awareness about health in several developing countries and high cost of drugs are anticipated to restrain the global pernicious anemia treatment market during the forecast period.
Request to View Brochure of Report -
The global pernicious anemia treatment market can be segmented based on the route of administration of drug, region, and distribution channel. Based on the route of administration, the pernicious anemia treatment market can be classified into parenteral, oral, nasal, and topical. The parenteral route segment accounts for a dominant share of the market due to higher availability and stability of drugs in the injectable form and major requirement of drugs in the injectable form during urgencies .In terms of distribution channel, the global pernicious anemia treatment market can be categorized into retail store, pharmacy, and e-commerce. The e-commerce segment is expected to account for a prominent market share in 2025 as shopping online offers convenience to consumers.
Comments
Post a Comment